Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
- Skjoth, Trine Vang
- Damci, Taner
- Donnet, Jean-Paul
- Endahl, Lars
- Vaag, Allan
- Niskanen, Leo
- Leiter, Lawrence A.
- Franek, Edward
- Weng, Jianping
- Munoz-Torres, Manuel
Publication date
January 2012
DOI Publisher
Bioscientifica Journal
Acta EndocrinologicaAbstract
Objective: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30)
Add to ORKG